This time last year there were no immune checkpoint inhibitors approved by the U.S. Food and Drug Administration (FDA) for treating the most common form of bladder cancer—urothelial carcinoma. The approval of avelumab (Bavencio) earlier this week means there are now four of these revolutionary immunotherapeutics in the armamentarium.
Read More
Earlier this week, the U.S. Food and Drug Administration (FDA) announced that it had approved a new immune checkpoint inhibitor, durvalumab (Imfinzi), for the treatment of certain patients with the most common form of bladder cancer—urothelial carcinoma.
Read More
Last week, the U.S. Food and Drug Administration (FDA) announced that it had approved expanding the use of the immunotherapeutic nivolumab (Opdivo) to include the treatment of certain patients with …
Read More
Last week, the U.S. Food and Drug Administration (FDA) increased the number of cancer types for which immunotherapeutics known as checkpoint inhibitors are an approved treatment option. On Tuesday, the …
Read More
Bladder cancer is the fifth most common cancer in the United States, predominantly affecting men in the later decades of life. However, this disease can also arise as a secondary …
Read More